CD274 and neoplasm: rs28459155 associated with lower odds of being a responder in Miao et al., Rizvi et al., and Hugo et al. but higher odds of being a responder in Van Allen et al., Snyder et al., and Riaz et al. As a comparison to current ICB biomarkers, we also evaluated association of tumor mutation burden (TMB) and expression levels of PD-L1, PD-1, and CTLA-4 with responder status and found no significant associations (Fig. 5E).